Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Mesoblast Limited (MESO) Price & Performance

Global E Online LtdTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Mesoblast Limited — how do they compare? Global E Online Ltd trades at $40.8 (market cap $6.90B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Global E Online Ltd is far larger — about 3.2× Mesoblast Limited's market cap, and Global E Online Ltd is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

GLBEMESO
Market Cap
$6.90B$2.16B
Sector
TechnologyTechnology
52-Week High
$42.32$20.96
52-Week Low
$27.54$12.88
Enterprise Value
$6.37B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.

GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO